Originally published by Destiny Pharma, 5 August 2024. This preclinical data was generated prior to AMR Bio’s acquisition of the XF platform and represents a key part of the scientific validation AMR Bio is building upon.
New data on XF-73 (Exeporfinium chloride) was presented at the Infection Prevention Society conference, 23–25 September 2024 in Birmingham, UK.
The data was generated from a study in which XF-73 was applied directly onto a methicillin resistant Staphylococcus aureus (MRSA) infected burn wound with subsequent monitoring of the spread of the MRSA into the bloodstream. When bacteria such as MRSA enter the bloodstream it can cause a life-threatening infection condition called sepsis which has a high mortality rate.
The headline results include:
- Following a single topical application of 25, 50 or 100 μg of XF-73, MRSA infection within the burn wound tissue was significantly reduced by up to 99.99% compared to the placebo treatment (p<0.05)
- Results from the three XF-73 dosed groups showed a significant 99.9% reduction of MRSA reaching the bloodstream (p<0.05)
- In one of the XF-73 treatment groups (50 μg), no MRSA had reached the bloodstream, resulting in the complete prevention of sepsis
Globally, it is estimated that there are approximately 9 million burn cases per year. Burn injuries contribute to over 250,000 fatalities with infections identified as the cause of 61% of post-burn deaths. Recent reports show the incidence of sepsis in burn patients ranges from 8% to 42% with related mortality from 28-65%. Staphylococcus aureus (including MRSA) is a common cause of post-burn infection, with reports that patients with burns had a prevalence of S. aureus of 57.8%.
Read the original announcement in full here: https://destinypharma.com/2024/08/05/xf-73-prevents-bacterial-invasion-of-bloodstream/